Understanding Lichen Planopilaris: Key Information

Clinical Overview

Lichen planopilaris (LPP) is a scarring alopecia belonging to the lichen planus group of inflammatory dermatoses. This condition is characterized by destruction of hair follicles through lymphocytic inflammation, ultimately causing permanent baldness in affected scalp regions. LPP accounts for 3-8% of scarring alopecias and predominantly affects middle-aged women, though men and children may be affected. Early recognition and treatment are critical, as prolonged inflammation leads to fibrosis and irreversible follicle destruction within months to years of disease onset.

Epidemiology

Lichen planopilaris shows female predominance (female-to-male ratio approximately 3:1) with peak incidence in the fourth to sixth decades of life. The condition occurs globally with no significant racial predilection, though some studies suggest higher prevalence in certain populations. Incidence is estimated at 0.75-1.5 cases per 100,000 population per year. LPP frequently coexists with lichen planus affecting skin or mucosa in 10-30% of cases, suggesting a systemic manifestation of lichen planus in some patients. However, isolated LPP without cutaneous or mucosal disease is more common.

Pathophysiology

Lichen planopilaris is mediated by CD8+ T lymphocytes that attack the hair follicle, particularly the stem cell region of the outer root sheath. The mechanism involves: (1) autoreactive T cell recognition of follicular antigens, (2) recruitment of lymphocytes to the follicle, (3) follicular destruction, and (4) fibrosis replacing the follicle. The trigger for autoimmunity is unknown but may involve viral antigens (hepatitis C, herpes viruses) or loss of immune tolerance to follicular self-antigens. Unlike alopecia areata where attack is transient, LPP causes progressive follicular destruction due to ongoing chronic inflammation. Histologically, dense lymphocytic infiltrate is seen around the follicular epithelium, accompanied by destruction of the follicle and eventual replacement by fibrosis.

Clinical Presentation

LPP typically presents insidiously with progressive alopecia affecting the scalp crown and vertex, though any scalp area may be involved. Unlike the patchy presentation of alopecia areata, LPP shows a diffuse pattern of hair loss progressing gradually over months to years. Patients report progressive thinning and hair loss concentrated on the crown. The scalp over affected areas appears atrophic, shiny, and pale—changes reflecting fibrosis and permanent follicle loss. Characteristically, the hairline remains intact ("preserved hairline sign"), helping distinguish LPP from androgenetic alopecia or traction alopecia. Patients often experience pruritus, scalp tenderness, or pain—distinguishing features from non-scarring alopecias. Follicular hyperkeratosis at the periphery of hair loss may create a keratotic ("follicular" or "violaceous") appearance. Some patients develop pervasive erythema or violaceous color to affected scalp. Exclamation mark hairs (tapered hairs at disease margin) may occasionally be seen, mimicking alopecia areata but less characteristic.

Diagnosis

Diagnosis requires combination of clinical presentation and scalp biopsy. Dermoscopy shows "white dots" (empty follicles), "red dots" or "violaceous dots" (perifollicular inflammation), and reduced follicular density. Scalp biopsy taken from the margin of active disease shows dense perifollicular and interfollicular lymphocytic infiltrate (predominantly CD8+ T cells), follicular destruction, and characteristic "lichenoid" changes. The interface dermatitis affects the follicle rather than the dermal-epidermal junction as in cutaneous lichen planus. Sebaceous glands and arrector pili muscles are destroyed. Advanced disease shows fibrosis replacing the follicle. Importantly, biopsy from the advancing margin of disease (where inflammation is active) yields better diagnostic information than biopsy of established scarred areas. Patients should be examined for cutaneous lichen planus (violaceous papules on skin) or oral lichen planus (white lacy patterns on mucosa), though LPP may occur in isolation.

Treatment Algorithm

Early intervention is critical in LPP because prolonged inflammation causes irreversible follicular destruction and fibrosis. Treatment goals are to halt disease progression, suppress inflammation, and achieve regrowth if possible before extensive fibrosis develops.

First-line topical therapy includes topical corticosteroids (class III-IV potent steroids such as triamcinolone acetonide 0.1% cream or betamethasone dipropionate 0.05%) applied twice daily to affected scalp areas. Response rates are 30-40% with sustained improvement. Topical calcineurin inhibitors (tacrolimus 0.1% ointment or pimecrolimus 1% cream) offer steroid-sparing alternatives for patients unable to tolerate long-term steroid use. Response rates approach 40-50% in small series. These agents require 2-3 months of continuous application before benefit becomes evident.

First-line systemic therapy involves oral minoxidil (1-2.5 mg daily), which has shown efficacy in LPP with approximately 60-70% of patients achieving disease stabilization or improvement. The mechanism involves immunomodulation and stimulation of remaining follicles. Response typically requires 4-6 months of treatment.

Intralesional corticosteroids (triamcinolone 2.5-10 mg/mL) injected directly into scarred areas every 4-6 weeks provide local immunosuppression. Response rates of 50-60% with stabilization or improvement are reported. Combination of intralesional injections with systemic oral minoxidil often yields superior outcomes compared to monotherapy.

Systemic corticosteroids (prednisone 0.5-1 mg/kg daily with gradual taper over 6-8 weeks) achieve response in approximately 60-70% of patients with LPP according to multiple case series. However, long-term use carries risks including immunosuppression, osteoporosis, and metabolic complications. Short courses are generally preferred to prolonged therapy.

Second-line agents include oral retinoids (isotretinoin 0.5-1 mg/kg daily or acitretin at similar doses), which show response in 40-50% of patients with LPP. Cyclosporine (3-5 mg/kg daily) achieves response in 30-40% of refractory cases. Mycophenolate mofetil (500-1000 mg twice daily) has shown promise in open-label studies with approximately 50% achieving improvement. Hydroxychloroquine (200-400 mg daily) is sometimes used, particularly if cutaneous lichen planus is also present, with moderate efficacy (30-40% response). Pioglitazone (15-30 mg daily) is emerging as a potential therapy based on small series and case reports showing 50% response rates.

JAK inhibitors are emerging as potential therapy for LPP. Case reports and small series suggest ruxolitinib or baricitinib may benefit LPP, though no randomized trials have been completed. Topical JAK inhibitors are under investigation for scalp application.

Prognosis

Without treatment, LPP progresses relentlessly, causing extensive scarring alopecia and baldness over 5-20 years. With early treatment (particularly oral minoxidil and intralesional corticosteroids), approximately 40-50% of patients achieve disease stabilization. Regrowth is modest (10-30% improvement in density) and depends on disease duration at treatment initiation. Late intervention after extensive fibrosis develops results in treatment-resistant disease. The critical therapeutic window appears to be within 6-12 months of symptom onset, before irreversible follicular destruction is complete.

When to See a Dermatologist

Women presenting with progressive scalp alopecia, particularly with pruritus, scalp pain, or preserved hairline, warrant immediate dermatology evaluation for possible LPP. Scalp biopsy is often necessary to confirm diagnosis and direct treatment. Patients with concurrent cutaneous or oral lichen planus should specifically be evaluated for scalp involvement.

Frequently Asked Questions

Is lichen planopilaris the same as androgenetic alopecia? No. LPP is an inflammatory scarring alopecia while androgenetic alopecia is non-scarring. LPP typically presents with preserved hairline and scalp symptoms (pruritus, pain), whereas androgenetic alopecia causes gradual miniaturization without inflammation.

Will my hair regrow with treatment? With early treatment, some regrowth of remaining follicles may occur; however, follicles destroyed by fibrosis will not regenerate. Early intervention maximizes chances for regrowth and disease stabilization.

How quickly does LPP progress? Disease progression varies substantially: some patients show slow progression over years while others rapidly progress over months. Without treatment, extensive baldness typically develops over 5-10 years.

Can I get lichen planus on my skin or in my mouth if I have scalp LPP? Approximately 10-30% of LPP patients develop cutaneous or mucosal lichen planus, suggesting systemic disease in some individuals. Regular examination for skin and oral lesions is appropriate.

References